Nogova,
Lucia
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany
2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands
3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
4. Novartis Pharma AG, Basel, Switzerland
5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States
6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States
8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany
9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;
Boellaard,
Ronald
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany
2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands
3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
4. Novartis Pharma AG, Basel, Switzerland
5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States
6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States
8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany
9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;
Kobe,
Carsten
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany
2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands
3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
4. Novartis Pharma AG, Basel, Switzerland
5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States
6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States
8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany
9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;
Hoetjes,
Nikie
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany
2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands
3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
4. Novartis Pharma AG, Basel, Switzerland
5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States
6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States
8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany
9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;
/persons/resource/persons147352
Zander,
Thomas
Klinisches PET, Neurologische Abteilung, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;
Gross,
Stefan Hubert
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany
2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands
3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
4. Novartis Pharma AG, Basel, Switzerland
5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States
6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States
8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany
9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;
Dimitrijevic,
Sasa
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany
2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands
3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
4. Novartis Pharma AG, Basel, Switzerland
5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States
6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States
8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany
9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;
Pellas,
Theodore
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany
2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands
3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
4. Novartis Pharma AG, Basel, Switzerland
5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States
6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States
8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany
9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;
Eschner,
Wolfgang
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany
2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands
3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
4. Novartis Pharma AG, Basel, Switzerland
5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States
6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States
8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany
9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;
Schmidt,
Katja
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany
2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands
3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
4. Novartis Pharma AG, Basel, Switzerland
5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States
6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States
8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany
9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;
Bangard,
Christopher
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany
2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands
3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
4. Novartis Pharma AG, Basel, Switzerland
5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States
6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States
8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany
9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;
Hayes,
Wendy
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany
2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands
3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
4. Novartis Pharma AG, Basel, Switzerland
5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States
6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States
8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany
9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;
/persons/resource/persons147315
Thomas,
Roman K.
Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;
/persons/resource/persons147154
Dietlein,
Markus
Translational Neurocircuitry, Research Groups, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;
Giaccone,
Giuseppe
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany
2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands
3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
4. Novartis Pharma AG, Basel, Switzerland
5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States
6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States
8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany
9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;
Hoekstra,
Otto S.
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany
2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands
3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
4. Novartis Pharma AG, Basel, Switzerland
5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States
6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States
8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany
9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;
Lammertsma,
Adriaan A.
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany
2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands
3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
4. Novartis Pharma AG, Basel, Switzerland
5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States
6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States
8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany
9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;
Wolf,
Juergen
1. Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, 50924 Cologne, Germany
2. Department of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, Netherlands
3. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
4. Novartis Pharma AG, Basel, Switzerland
5. Novartis Pharmaceuticals Corp., East Hanover, NJ, United States
6. Department of Radiology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
7. Novartis Institutes for BioMedical Research, Cambridge, MA, United States
8. Chemical Genomics Center of the Max Planck Society, Dortmund, Germany
9. Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands;